|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammatory Pathways in Liver Homeostasis and Liver Injury显示文摘 | Frank Tacke Tom Luedde Christian Trautwein | 2009 | Clinical Reviews in Allergy & Immunology2009，，1： | 3 |
| 2 | Micro‐RNA profiling reveals a role for miR‐29 in human and murine liver fibrosis显示文摘 | Christoph Roderburg Gerd‐Willem Urban Kira Bettermann Mihael Vucur Henning Zimmermann Sabine Schmidt J?rn Janssen Christiane Koppe Percy Knolle Mirco Castoldi Frank Tacke Christian Trautwein Tom Luedde | 2011 | Hepatology2011，，1： | 3 |
| 3 | Inflammatory Pathways in Liver Homeostasis and Liver Injury显示文摘 | Frank Tacke Tom Luedde Christian Trautwein | 2009 | Clinical Reviews in Allergy & Immunology2009，，1： | 1 |
| 4 | High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo显示文摘 | Frank Tacke Torsten Wüstefeld Rüdiger Horn Tom Luedde Annavarapu Srinivas Rao Michael P. Manns Christian Trautwein Georg Brabant | 2005 | Journal of Hepatology2005，，5： | 1 |
| 5 | Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma显示文摘 | Tom Luedde Naiara Beraza Vasileios Kotsikoris Geert van Loo Arianna Nenci Rita De Vos Tania Roskams Christian Trautwein Manolis Pasparakis | 2007 | Cancer Cell2007，，2： | 1 |
| 6 | Long-term survival of a HCC-patient with severe liver dysfunction treated with sorafenib显示文摘Hepatocellular carcinoma (HCC) is the most common primary cancer of the liver. Prognosis and treatment options are stage dependent. In general, prognosis of patients with unresectable HCC is poor, especially for those patients with impaired liver function. Whereas treatment with the novel molecular tyrosine kinase inhibitor sorafenib (Nexavar) was shown to result in prolonged survival in patients with preserved liver function, its' possible application in HCC-patients with strongly impaired liver function has not been clearly assessed. Here, we report on a 47-year-old male patient who presented with Child-Pugh class C liver cirrhosis and multifocal, non-resectable HCC. The patient was treated for 27 mo with Sorafenib, which was not associated with major drug-related side effects. During treatment, a reduction in tumour size of 24% was achieved, as assessed by regular CT scan. Moreover,within the 27 mo interval of stable tumour disease, liver function improved from Child-Pugh class C to class A. | Christoph Roderburg Jhenee Bubenzer Michael Spannbauer Nicole do O Andreas Mahnken Tom Luedde Christian Trautwein Jens JW Tischendorf | 2010 | World Journal of Hepatology2010，2，6： | 1 |
| 7 | 1KK1 and IKK2 cooperate to maintain bile duct integrity in the liver 显示文摘 | Tom Luedde Jan Heinrichsdorff Rossana de Lorenzi | 2008 | PNAS2008，28，105： | 1 |
| 8 | Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance显示文摘 | Tom Luedde Neil Kaplowitz Robert F. Schwabe | 2014 | Gastroenterology2014，，4： | 1 |
| 9 | Regulation of plasma erythropoietin in chronic liver disease显示文摘In a May-issue of the World Journal of Gastroenterology, there is a very interesting study by Bruno et al. on erythropoietin (EPO) levels in patients with chronic liver disease. We have very recently reported a similar, but much larger study by Tacke et al. on the role of EPO in chronic liver disease. By comparing Bruno's results with our patient cohort and applying their | Frank Tacke Tom Luedde Michael P.Manns Christian Trautwein | 2004 | World Journal of Gastroenterology2004，10，19： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员